Reggio Emilia

• The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) Not authorised
  2024-511325-67-00 5 Chronic kidney disease
• A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in EGPA- RACE-MATE Not authorised
  2024-514794-22-01 4 Eosinophilic granulomatosis with polyangiitis (EGPA)
• A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART) Pending
  2024-515287-31-00 5 Giant Cell Arteritis
• Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI—ODYSSEY Pending
  2024-515462-14-00 6 Long term potential effect of repeated exposure to either a linear or
• A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma posit … Pending
  2024-515555-38-01 4 NON SMALL CELL LUNG CANCER
• CardioPulmonary resuscitation with Argon (CPAr) trial Pending
  2024-516864-27-00 4 Cardiac arrest
• Use of Sulodexide (VESSEL®) for the prevention of a new episode in elderly patients who have had a first episode of deep vein thrombosis and … Pending
  2024-517796-21-00 5 Prevention of recurrence after a first episode of Venous Thromboemboli
• A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY … Pending
  2024-517861-18-00 5 Idiopathic IgA nephropathy (IgAN)
• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br … Pending
  2024-518026-32-00 5 Invasive Breast Cancer
• Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending
  2024-518386-95-02 4 Non small-cell lung cancer
• Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial) Pending
  2024-518388-37-00 4 Intermediate risk prostate cancer
• Clinical trial investigating the efficacy of gilteritinib and chemotherapy treatment in patients with Acute myeloid leukemia Pending
  2024-518617-25-00 4 newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
• A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm … Pending
  2024-519087-41-00 5 Breast cancer is the most common form of cancer among women in North A
• A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastat … Pending
  2024-519519-32-00 4 urothelial cancer
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R … Pending
  2024-519818-31-01 5 Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresec
• Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiot … Pending
  2024-520081-65-00 4 NSCLC non-small cell lung cancer
• Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA T … Pending
  2024-520093-34-00 5 Acinar cell prostatic carcinoma
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Li … Pending
  2025-521666-10-01 4 Mantle Cell Lymphoma
• TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of ly … Pending
  2025-521827-61-00 4 refractory/relapsed multiple myeloma
• A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending
  2025-522084-15-00 10 metastatic NSCLC patients
• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 5 Relapsed/refractory primary central nervous system lymphoma
• An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Pending
  2025-523579-47-00 4 moderate to severe rheumatoid arthritis (RA)

Showing 1–24 of 241 trials